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I ABSTRAK 
PERBANDINGAN DI ANTARA ANALGESIA INTRAVENA KAWALAN 
PESAKIT (PCA) MORPHINE DENGAN ANALGESIA INTRA VENA 
KA WALAN PESAKIT (PCA) TRAMADOL DI KALANGAN PESAKIT YANG 
rvtENJALANI PEMBEDAHAN MAJOR 
Pengenalan: Kejayaan pembedahan maJor bergantung sebahagiannya kepada 
keberkesanan pengawalan kesakitan selepas pembedahan. Ianya dapat dicapai 
dengan pemberian morphine melalui system " PCA'. Tramadol adalah 'Opioid' 
penahan sakit yang lemah. Ianya bertindak terutamanya melal ui reseptor opioid 'J.l'. 
Tujuan kajian ini adalah untuk menentukan keberkesanan intravena 'PCA' Tramadol 
berbanding dengan "PCA' Morphine dari segi kawalan kesakitan, kesan sedasi, dan 
kesan sampingan yang lain seperti rasa loya, muntah dan kegatalan. 
Kaedah: Kajian ini dijalankan secara rawak, dan 'double- blind' ke atas 160 pesakit 
ASA I dan I I yang terpilih dan telah dibahagikan kepada dua kumpulan melalui 
kaedah sampul surat tertutup. Selepas pembedahan, kumpulan 'PCA' (M) morphine 
(n = 80) menerima dos permulaan intravena morphine 0.1 mg/kg diikuti infusi 'PCA' 
sebanyak 1 mg (lmg/ ml) seperti diperlukan. Kumpulan 'PCA' (T) tramadol (n = 80) 
menerima dos pennulaan 2.5 mglkg diikuti infusi 'PCA' sebanyak 10 mg ( 10 mg/ 
ml ) seperti diperlukan. Tempoh jarak kunci keselamatan adalah I 0 min it. Semua 
pesakit tidak menerima basal infusi. Di bilik pennulihan, pesakit diberikan oksigen 
X 
melalui 'face mask' dan pemerhatian tahap kesakitan mengikut 'Modified Pain 
Score', tahap sedasi mengikut 'Ramsay Sedation Score', kadar pemafasan, rasa Ioya, 
muntah, kegatalan, tekanan darah dan kadar nadi dicatatkan. Pesakit sekali lagi 
diperiksa selepas 30 minit di bilik pemulihan. Pemerhatian diteruskan di wad selepas 
4 jam, 24 jam dan 48 jam pembedahan. 
Keputusan: Menunjukkan tiada perbezaan di dalam data demografik di antara dua 
kumpulan ini (p > 0.05). Purata tahap kesakitan bagi kumpulan Tramadol untuk 
untuk setiap 30 minit, 4 jam, 24 jam dan 48 jam selepas pembedahan adalah 1.32 ± 
0.79, 1.04 ± 0.79, 0.35 ± 0.48 dan 0.09 ± 0.33 setiap satu. Manakala purata tahap 
kesakitan bagi kumpulan Morphine untuk setiap 30 minit~ 4 jam, 24 jam dan 48 jam 
selepas pembedahan adalah 1.35 ± 0.99, 1.14 ± 0.81, 0.40 ± 0.54 dan 0.10 ± 0.34 
setiap satu. Tiada perbezaan yang ketara untuk tahap kesakitan bagi setiap te1npoh 
yang dinyatakan di antara kedua dua kumpulan tersebut (p>0.05). Purata tahap 
sedasi bagi kumpulan Tramadol untuk setiap 30 minit~ 4 jam, 24 jam dan 48 jam 
selepas pembedahan adalah 0.90 ± 0.74, 0.56 ± 0.59, 0.08 ± 0.27 dan 0.02 ± 0.16 
setiap satu. Manakala purata tahap sedasi bagi kumpulan Morphine untuk setiap 30 
minit, 4 jam, 24 jam dan 48 jam selepas pembedahan adalah 0.84 ± 0. 70, 0.46 ± 
0.64, 0.08 ± 0.27 dan 0.01 ± 0. I I setiap satu. Tiada perbezaan yang ketara untuk 
tahap sedasi bagi setiap tempoh yang dinyatakan di antara kedua dua kumpulan 
tersebut (p>0.05). Kajian juga menunjukkan tiada perbezaan yang ketara antara 
kedua-dua kumpulan dari segi kejadian loya, muntah dan kegatalan. 
XI 
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Kesimpulan: Kajian ini menunjukkan 'PCA' Tramadol adalah sama 
keberkesanannya berbanding dengan 'PCA' morphine dari segi pengawalan 
kesakitan selepas pernbedahan major. Kesan sedasi, rasa loya, muntah atau kegatalan 
adalah sama di dalam kedua-dua kumpulan . 
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ABSTRACT 
A CO:MP ARA TIVE STUDY OF INTRA VENOUS PATIENT- CONTROLLED 
ANALGESIA MORPHINE AND TRAMADOL INPATIENTS UNDERGOING 
MAJOR OPERATION 
Introduction: The success of major surgery depends partly on providing effective 
post-operative pain relief, which can be achieved by morphine administration via 
PCA system. Tramadol is a weak opioid analgesic, which act mainly on f..L-opioid 
receptor. The purpose of this study was to evaluate the effectiveness of intravenous 
patient-controlled analgesia (PCA) Tramadol in comparison with PCA Morphine in 
tenn of analgesic properties, sedation and other side effects such as nausea, vomiting 
and pruritus. 
Methods: A randomized, double-blinded study was conducted on 160 selected ASA I 
and II patients who were divided into two groups by a closed envelope technique. 
Following surgery, the PCA morphine (M) group (n=80) received a loading dose of 
0.1 mglkg of intravenous morphine followed by I mg ( 1 mg/ml) of PCA infusion as 
required. The PCA tramadol (T) group (n=80) received a loading dose of 2.5 mg/kg 
of intravenous tramadol followed by 10 mg (10 mg/ml) ofPCA infusion as required. 
The lockout intervals for both groups were 10 minutes. None of the patients received 
baseline infusion. In the recovery room, patients were given oxygen via facemask 
and monitored for pain score according to Modified Pain Score, sedation score 
xiii 
according to Ramsay Sedation Score, respiratory rate, nausea, vomiting, pruritus, 
blood pressure and pulse rate. Patients were evaluated at the end of 30 minutes in 
recovery room. After 4 hours, 24 hours and 48 hours post operation, patients were 
again evaluated in the ward. 
Results: Showed no difference in the demographic data between the two groups 
(p>0.05). The mean pain score in tramadol group at 30 minutes, 4 hours, 24 hours 
and 48 hours post operation were 1.32 ± 0.79, 1.04 ± 0.79, 0.35 ± 0.48 and 0.09 ± 
0.33 respectively. Whereas, the mean pain score in morphine group at 30 minutes, 4 
hours, 24 hours and 48 hours post operation were 1.35 ± 0.99, 1.14 ± 0.81, 0.40 ± 
0.54 and 0.10 ± 0.34 respectively. There were no significant differences in the mean 
pain score between the t\vo groups at each duration of assessment (p>0.05). The 
mean sedation score in tramadol group at 30 minutes, 4 hours, 24 hours and 48 hours 
post operation were 0.90 ± 0.74, 0.56 ± 0.59, 0.08 ± 0.27 and 0.02 ± 0.16 
respectively. Whereas, the mean sedation score in morphine group at 30 minutes, 4 
hours, 24 hours and 48 hours post operation were 0.84 ± 0.70, 0.46 ± 0.64, 0.08 ± 
0.27 and 0.01 ± 0.11 respectively. There were no significant differences in the mean 
sedation score between the two groups at each duration of assessment (p>0.05). 
There were also no significant differences between the two groups in the incidence 
of nausea, vomiting and pruritus. 
xiv 
Conclusion: This study indicates that PCA tramadol is suitable to be used as an 
alternative to PCA morphine in controlling pain following major surgery. The 
incidence of sedation, Dallfiea and pruritus were similar in the two groups. 
XV 
I 
~ 
CHAPTER 1: INTRODUCTION 
Postoperative recovery after major surgery depends on various factors, such as adequate 
pain relief, nausea or vomiting and mobilization. After surgery, 20% - 40% of patients 
would experience pain of moderate intensity and another would experience severe pain 
(50% - 70o/o). A reduction in the surgical stress responses (endocrine, metabolic and 
inflammatory) will lead to a reduced incidence of postoperative organ dysfunction and 
thereby to an improved outcome. The stress response has been termed "the integrated, 
adaptive lining web of neuroendocrine, immunologic, and intercellular biochemical signals 
evoked by tissue injury". The dominant neuroendocrine response to pain involved 
hypothalamic-pituitary adrenocortical and sympathoadrenal interactions (Miller, R.D .. 
1999). 
As afferent neural stimuli and activation of the autonomic nervous system and other 
reflexes by pain may serve as major release mechanisms of the endocrine metabolic 
responses and thus contribute to various organ dysfunctions. Segmental reflex responses 
associated with surgery include increased skeletal muscle tone and spasm with increases in 
oxygen consumption and lactic acid production (Miller, R.D., 1999). 
Sympathetic activation increases efferent sympathetic tone to all viscera and releases 
catabolic hormone (catecholamines, cortisol and glucagons) and decreases anabolic 
hormones (insulin and testosterone) from gland hormones. This causes tachycardia. 
increased stroke volume, cardiac work and myocardial oxygen consumption. Tone is 
.. 
decreased in the gastrointestinal and urinary tracts. Pain following major operations or 
trauma has direct effects on respiratory function. Immobilization or bed rest due to pain in 
peripheral sites can also indirectly affect respiratory as well as hematologic function. 
(Morgan, G.E. et a/., 1996). Moderate to severe acute pain, regardless of site, can affect 
nearly every organ function and adversely influence postoperative morbidity and mortality. 
Pain relief may be a powerful technique to modify surgical stress responses (Kehlet, H. et 
a/., 2001 ). 
Despite advances in the knowledge of acute pain mechanisms and treatment, management 
of acute pain is often ineffective, especially in general ward. The prospect of moderate or 
severe pain is a common concern of patients when contemplating major operations. The 
principal intent of pain control is to substantially reduce or possibly eliminate postoperative 
pain. Pain may also have other physical as well as psychological sequelae, including 
impaired respiratory function, long term pain depression, and posttraumatic stress reactions. 
Major operations are stressful psychological and physiological events, and patient may fell 
traumatized despite otherwise successful operations (Kehlet, H. eta/., 200 I). 
The purpose of postoperative analgesia is to prevent pain and inhibit the transmission of 
nociceptive stimuli that leads to stress responses and long term changes in sensory function 
(Wilder-Smith C. H. et al, 1999). Most analgesia trials have focused on the intensity or 
location of pain, rather than assessing whether improved analgesia can modify the 
traumatic experience 
2 
Prevention of postoperative sensitization has been attempted by various method including 
oral medication, suppositories, intramuscular, intravenous or regional technique with 
varying outcome (Wilder-Smith, C.H. eta/., 1999). More recently, patient satisfaction with 
• ~ opioids has improved with the introduction ofPCA system (Chen, P.P. eta!, 2001). 
Tramadol has been used in numbers of European countries for many years and has been 
approved by _the Food and Drug Administration (FDA) in the United States (Miller, R.D., 
1999). Tramadol is a weak opioid analgesic, mainly act on J.1 opioids receptor but also has 
additional analgesic action through the inhibition of neuronal re-uptake of neurotransmitter 
5-hydroxytryptamine and noradrenaline as well as stimulation of the released of 5-
hydroxytryptamine. Tramadol has not been associated with clinically significant respiratory 
depression unlike conventional opioids (Bloch, M.B. eta/, 2002). 
Morphine is the most commonly used opioids analgesic in PCA system. The purpose of this 
study is to evaluate whether an analgesic dose of tramadol using PCA system is similar to 
conventional opioids, morphine in tenns of effectiveness, sedation and common side effects 
of opioids such as nausea, vomiting and pruritus. 
Another aim of this study is to evaluate the suitability of PCA tramadol as an alternative to 
PCA morphine in acute pain service (APS) in postoperative patients in Universiti Sains 
Malaysia Hospital (HUSM). 
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CHAPTER 2: LITERATURE REVIEW 
2.1. TRAMADOL 
2.1.1 History 
Tramadol wa~ first introduced in 1977 in Germany as a weak opioid analgesic. It is a 
synthetic opioid of the aminocyclohexanol group. It was believed initially to produce 
analgesic effect, only via J.l-receptor. In the late 1980s, it has been discovered that it has 
another mode of action due to its low risk of respiratory depression, tolerance and 
dependence (Langford, R.M eta/, 1998). Tramadol inhibits re-uptake of neurotransmitters, 
serotonin and noradrenaline (Bloch, M.B. eta/, 2002). 
It is a racemic mixture of two sinergestic enantiomers, with ( + )-tramadol producing greater 
serotonin reuptake inhibition, whereas (-)-tramadol inhibits noradrenaline reuptake. The 
administration of tramadol does not induce histamine release, an important factor in 
anaphylactoid reactions (Roux, L. et. a!, 2000). 
2.1.2 Classification 
Tramadol is a synthetic analgesic of the aminocyclohexanol group with features a centrally 
acting analgesic drug and opioids like effects (Murphy, D.B., eta/., 1997). 
4 
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2.1.3 Physicochemical characteristics 
The chemical designation is (+)trans -2- (dimethyl aminomethyl)- ( m- methoxyphenyl) 
_ cyclohexanol - hydrochloride (Roux, L. et a/, 2000). Tramadol is white, odourless 
powder that dissolves easily in water or alcohol and available in numerous preparation. It 
provides central analgesic potency of an opioid but lacks most of the opioids critical and 
unrelated side effects such as respiratory depression, constipation, abuse, dependence or 
other opioids related problems (Langford, R.M. eta/, 1998). 
2.1.4 Uses 
Tramadol is used for pain n::lief especially in acute pain service or alternatively in chronic 
pain since it has opioid analgesia with less opioid side effects such as respiratory 
depression, tolerance and dependence. 
2.1. 5. Contraindication 
Tramadol is contraindicated in patients with history of allergic to tramadol and allergic to 
sedative or psychotropic drugs. Those who are receiving MAO inhibitors within 14 days 
and those with alcohol intoxication are also contraindicated. 
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2.1.6. Dosage 
In clinical practice, the loading dose ranges for IV Tramadol administration in pain control 
are approximately 1-3 mg/kg (Nagaoka, E. et al. , 2002) with maximum dose of 100 mg 
(S ilvasti, M. et al., 2000). 
2.1.7. Pharmacokinetics 
The analgesic effect of Tramadol HC I is produced by both parent drugs (racemix mixture) 
and the M I (mono-o-desmethyltramadol) metabol ite. Tramadol is being metabolized by 
hepatic cytochrome P450 to desmethylated compounds. A major metabolite, (+)-0-
desmethyl tramadol is responsible for the weak !l-opioid agonist effect and requires 
sparteine oxygenase enzyme for its formation . (Roux. L. eta!. 2000) 
This sparteine oxygenase enzyme is deficient in up to 7% of Caucasian individuals. leading 
to the reduced formatio n of (+)-0-desmethyl Tramadol and reduced analgesic effect m 
these ·poor metabolizers'(Roux, L. et a!, 2000). The CYP206* I 0 allele which IS 
panicu larly associated with these enzyme is common in Asian people (Gan. S.H .. et a!. 
2002). 
When administered orally, tramadol is rapidly absorbed (Kaye, K., 1998) and reaches peak 
effect after 2-3 hours. Peak plasma level is achieved in I hour (Raux, L. et al, 2000). When 
ad min istered intravenous ly, the onset of action is within 7 minutes and reaches peak plasma 
level in 25 minutes (Raux, L. et al, 2000). The bioavailability is 73-79%. Tramadol is 20% 
6 
protein bound and crosses placenta and blood-brain barrier. The plasma clearance is 6.4 
ml/min/kg with 30°/o excreted unchanged and 60% excreted as metabolite. The volume of 
distribution (Yo) is 2.6- 2.9 L/kg and the half-life is about 7 hours (Lehmann, K.A. eta/., 
1994). 
2.1.8. Pharmacodynamics 
Initially, it was believed that tramadol produces opioid analgesia only via J.t-receptor. The 
opioid activity of this drug is produced by both low affinity binding of the parent 
. ~ 
r ~ 
compound and higher affinity binding of the 0-demethylated metabolite M I to J.t-recepto~ . 
M I is 6 times more potent than the parent drug. In late 1980s, another mode of action has 
been discovered due to its low risk of respiratory depression, tolerance and dependence 
i 
(Roux. L. eta/, 2000). 
It was found that tramadol inhibits the re-uptake of neurotransmitters, serotonin and 
noradrenaline. It is a racemic mixture of two sinergestic enantiomers, with (+)-tramadol 
producing greater serotonin reuptake inhibiti0n, whereas (-)-tramadol inhibits noradrenaline 
reuptake. The analgesic effect of tramadol begins approximately within 7 minutes after 
intravenous administration (Roux, L. eta/, 2000). In contrast to morphine, tramadol has not 
been shown to cause histamine release. At therapeutic doses, tramadol has no effect on 
heart rate, left- ventricular function or cardiac index (Roux, L. eta/, 2000). 
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2.1.8 (a) Central Nervous System 
Tramadol causes anxiety, confusion, dizziness, headache, tremor, ataxia, hypertonia, 
paraesthesia, stupor, migraine and convulsion. Virtually, tramadol has no dependence 
potential (Vickers, M.D. et al., 1992). 
2.1.8 (b) Cardiovascular System 
Tramadol can cause hypertension, vasodilatation, syncope, orthostatic hypotension (1%), 
tachycardia (<1%), abnormal ECG and palpitltion. 
2.1.8 (c) Gastrointestinal System 
Abdominal pain, constipation, diarrhoea, dry mouth, nausea and vomiting may occur. 
2.1.8 (d) Respiratory svstem 
In high doses, it can cause dyspnoea. At an equi-analgesic dose, tramadol has much less 
effect on the respiratory centre than morphine. Thus, it has a higher therapeutic ratio with 
transient effects on respiratory system (Vickers, M.D. et al, 1992). 
2.1.8 (e) Skin 
Rarely, tramadol can cause vasodilatation and urticaria(< 1 %) 
2.1.8 (f) Genitourinarv System 
Albuminuria, micturation disorder, oliguria, urinary retention may occur. 
8 
2.1.8 (g) Special Senses 
Visual disturbances (I%), tinnitus and deafness are rare. 
2.1.8 (h) Miscellaneus 
Some patients may develop hypertonia (1 %). 
2.1.9. Overdosage 
The effects of tramadol overdosage are typical as the overdosage of other opioid analgesics 
such as miosis, vomiting, cardiovascular collapse, sedation, coma, respiratory depression 
and/or seizures (Roux. L. et al, 2000). 
2.1.1 0. Interactions 
. ' t Drugs that inhibit or induce P-450 enzymes can influence the effects of tramadol. 
Interactions have previously been reported with carbamazepine. cimetidine and quinidine. 
Patients receiving monoamine oxidase inhibitors are at ri sk of hypertensive crisis. 
Tramadol is probably safe to be used in conjunction with anticoagulant therapy (Roux. L. er 
al, 2000). 
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2.1 MORPHINE 
2.2.1 History 
Morphine is a prototype opioid agonist to which all other opioids are compared. It is a pure 
opioid agonist and tertiary amine being isolated from poppy plant in 1805 by Serturner. It 
acts on the )..1. & K receptor. Morphine is a weak base, water soluble in vitro but become 
poorly lipid soluble in vivo (Stoelting, R.K. , 1999). 
Figure 2.1: Chemical Structure of iv1orphine 
c 
6 
0 
Morphine 
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2.2.2. Physical properties 
Morphine is available in the form of aqueous morphine sulphate with pKa of 7.9 (basic). 
2.2.3 Clinical uses 
Morphine can be used as: 
1. Analgesic with various method administration including parenteral, intrathecal. and 
epidural. 
2. Supportive treatment for pulmonary oedema. 
3. Premedication for surgery. 
4. Induction agent for general anaesthesia. 
5. Brief relieve of anxiety in serious and fri ghtening disease accompanied by pain such 
as trauma. 
2.2.4 Contraindication 
Morph ine is contraindicated in patients with asthma. e lderl y. high intracranial pressure. 
hypovolaemia, liver and kidney disease and neonates. 
2.2.5 Dosage 
The intravenous dosage of morphine in an adult is O.IOmg/kg. When high dose anaesthesia 
is requi red, the intravenous dose is 0.5-3 mg/kg. It can cause respiratory depress ion within 
II 
7 minutes if administered intravenously and 30 minutes if administered intramuscularly 
(Stoelting, R.K., 1999). 
2.2.6 Pharmacokinetics 
Oral morphine is subject to extensive presystemic or first-pass metabo lism and only about 
20% of a dose reaches the systemic circulation (Laurence, D.R. et al, 1997). Thus, 
absorption from the gastrointestinal tract is not reliable. Morphine is usually administered 
intravenously, thus eliminating the unpredictable influence of drug absorption (Stoelting, 
R.K., 1999). The onset of action is within l 0 minutes (Miller, R.D., 1999) and the peak 
effect after IV administration of morphine requi res about 45 minutes. The half-life is about 
6 hours. Morphine is 20-35% protein bound. The plasma clearance is 15 ml/min/kg (Mi ller. 
R.D., 1999) with 3-4 Llkg volume distribution (V0 ) (Stoelting, R.K .. 1999). Morphine also 
crosses the placental membrane and has been fo und in breast milk. 
Morphine is metabolized by both li ver and kidney. The conjugated metabolites include 
morphine-3-glucoruonide morphine-6-glucuronide (more potent than morphine) and some 
sulphate (S toelting, R.K. , 1999). Morphine is main ly excreted as morphine-3-glucoronide 
(M3G) and I 0% is excreted unchanged in the urine (Laurence, D.R.et a/. , 1997). A small 
amount of the glucoronide conjugate is excreted in the bi le and 7-10% is excreted in the 
feces. 90% of excretion occurs in the first 24 hours while the rest is excreted within 48 
hours (Stoelting, R.K. , 1999). 
I :! 
( 
2.2. 7 Pharmacodynamics 
Morphine produces its analgesic effects via stereospecific opioid receptors at presynaptic 
and postsynaptic sites in the central nervous system (principally the brainstem and spinal 
cord) and outside the central nervous system in peripheral tissue. The mechanism of its 
analgesic effect is due to 1..1. agonist action. 
2.2.7 (a) Central Nervous Svstem 
Morphine exerts its potent analgesic properties through its effects on ).l1 (suprespinal and 
spinal analgesia) receptor and )...1.2 (spinal analgesia) receptor causing selective to dull pain 
and reduce affective response. J...1.2 receptors are responsible for hypoventilation, 
bradycardia, constipation and physical dependence (Stoelting, R.K. , 1999). The therapeutic 
effects of morphine include euphoria, anxiolysis and feelings of relaxation. Morphine 
causes respiratory depression, in part by a direct effect on the brain stem respiratory 
centers. Morphine depressed the cough reflex by direct effect on the cough center in the 
medulla. Other effects of morphine include sedation, increases intracranial pressure (ICP) 
and decreases cerebral blood flow (CBF). The EEG will show an increased voltage and 
lowered frequency of wave form pattern (Stoelting, R.K., 1999). 
13 
2.2.7 (b) Cardiovascular System 
In therapeutic doses, morphine does not usually exert major effects on cardiovascular 
system. If given in large doses, morphine can decrease blood pressure, decrease heart rate 
and cause peripheral vasodilatation. The decrease in systemic vascular resistance leads to a 
decrease in blood pressure. Postural hypotension resulted from peripheral vasodilatation 
and venous pooling (decrease venous return). The reduction in left ventricular end diastolic 
(L VED) pressure occurs as a result of dilatation of venous capacitance vessel. Sinus 
bradycardja may occur due to central vagal stimulation. The release of histamine, centrally 
mediated parasympathetic pathway, vagal induced bradycardia, direct and inrurect venous 
and arterial vasoclilatation and splanchnic sequestration of blood (Stoelting, R.K. , 1999). 
2.2.7 (c) Gastrointestinal Svstem 
Morphine can cause a decrease in prepulsive activity and increase in smooth muscle tone in 
anal and ileocolic sphincter. The resultant prolongation in gastrointestinal transit time is 
responsible for the constipating effect of morphine. The lower oesophageal sphincter 
pressure is decreased, the oesophageal reflux is increased and the hydrochloric acid (HCl) 
secretion is decreased by morphine (Stoelting, R.K. , 1999). 
2.2.7 (d) Respiratory svstem 
Bronchoconstriction may occur due to the released of histamine. The respiratory center is 
depressed due to decrease sensitivity of brainstem respiratory center to PaC02 leading to 
perioilic breatrung and apnoea. 10 mg of intravenous morphine will decrease tidal volume, 
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respiratory rate and resting PaC02 to 3 mmHg in a normal subject. In large doses (2mglkg), 
it will depress the minute ventilation and increase ETC02. Morphine also produces dose-
dependent depression of ciliary activity in the airways (Stoelting, R.K., 1999). 
2.2.7 (e) Skin 
Morphine can cause vasodilatation. 
2.2. 7 (f) Uterus 
Morphine crosses placenta and may result in direct depression on the uterus contraction in 
large doses. It can also cause muscle rigidity. 
2.2. 7 (g) Genitourinarv Svstem 
Morphine can increase the ureteric tone, causing contraction of dextrusor and vesicular 
muscle that may lead to the difficulty in micturition. It also has an antidiuretic effect. 
2.2.8 Overdosae:e 
The adverse etTects of morphine include rntosts, respiratory depression, euphoria and 
dependence. Rarely, morphine causes muscle rigidity. Overdosage of morphine resulted in 
marked miosis, asphyxia, severe hypoxaemia and convulsion (Stoelting, R.K., 1999). 
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2.2.9 Interaction 
The ventilatory effect of morphine may be exaggerated by amphetamine, phenothiazine, 
monoamine oxidase inhibitor and tricyclic anti depressants. This exaggerated response may 
reflex a lterat ion in the rate or metabolism pathway of the opioid. Sympathom imetic drugs 
appear to enhance analgesia produced by opioids (Stoelting, R.K., 1999). 
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'~: ~ . t" r • 2.3 PAIN 
"An unpleasant sensory and emotional experience usually associated with actual or 
potential tissue damage, or described in terms of such damage" (The International 
. Association for the Study of Pain, 1986). Pain is mainly a protective mechanism that occurs 
when tissues are being damaged. It is an unpleasant sensation and need to be relieved 
(Stoelting, R.K-., 1999). 
2.3.1. The importance of pain management 
I. Allow early mobilization and early discharge. 
2. Reduce hospitalization and nursing care which later will reduce the cost. 
3. Promote healing and improve perfusion. 
4. Easy pain control by the patient. 
5. Reduce personal anxiety especially for the children due to bad experience. 
6. Reduce postoperative complication. 
(Hutton, P. eta!., 2002) 
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2.3 .2. Pain Pathways 
Surgery produces local tissue damage with consequence release of inflammatory mediators 
(prostaglandin, histamine, serotonin, bradykinin, 5-hydroxytriptamine, substance P) and 
aeneration of noxious stimuli by A delta and C nerve fiber to the neuroaxis (Miller, R.D. , 
0 
1999). 
2.3.3. First Order Neurons 
The first order neurons, send their axon to spinal cord via the dorsal (sensory) spinal root at 
each cervical, thoracic and sacral level. Some unmyelinated afferent ( C ) fibers enter the 
spinal cord via the ventral nerve nerve (Motor) root. In dorsal hom. in addition to synapsing 
wi th second order neurons, the axons of first order neuron may synapse with interneurons 
and ventral hom motor neurons. Pain fibers from head are carried by V. VII. IX and X 
nerve (\!forgan, G.E. et a/., 2002). 
2.3.4. Second Order Neurons 
The second order neurons, segregated according to size, with large, myelinated fibers 
becoming medial and small , unmyelinated fibers becoming lateral (Morgan. G.E. et a! .. 
2002). 
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2.3.4 (a) The Spinothalamic Tract 
The axon of most second order neurons cross the midline to the contralateral side of the 
spinal cord before they form the spinothalamic tract and send their fibers to the thalamus, 
reticular formation, the nucleus raphe magnus and periaqueductal gray. The lateral 
spinothalamic (Neospinothalamic) tract projects mainly to the ventral posterolateral nucleus 
of the thalamus that give rise to discriminative pain such as location, intensity and duration 
of pain. 
FAST PAIN (NEOSPINOTHALAMIC): 
• 
• 
• 
Sharp pain, pricking , electric 
Felt within 0.1 sec after stimulation 
Transmitted through A delta fiber at 6-30 m/sec 
• Involvement of second order neuron 
• Terminated in thalamus-sensory cortex 
(Stoelting, R.K., 1999) 
The medial spinothalmic (Paleospinothalamic) tract projects to the medial thalamus and 
give ri se to autonomic and unpleasant emotional perceptions of pain (Morgan, G.E. et al .. 
2002). 
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SLOW PAIN (P ALEOSPINOTHALAMIC): 
• Burning, aching, throbbing, chronic 
• Begins only after I sec or more and sometime even minute 
• Widespread in the whole body except brain and spinal cord 
• Transmitted through C fibe r at 0.5- 2 m/s 
• More than two neurons involved 
• Widely terminated in brain stem 
• Only 1110- 114 sensory cortex involved 
• Poorly localized 
(S toelting, R.K .. 1999) 
2.3.4 (b) The Alternative Pain Pathwavs 
As wirh epicritic sensation. pain fibers ascend diffusely, ipsilaterally and contralaterally. 
Hence. some patients can sti ll complaint of pain in spite of ablation of the contralateral 
sp inothalamic tract. 
2.3.5. Third Order Neurons 
The third order neurons are located in the thalamus and send fibers to somatosensory areas 
1 and II in the post-central gyrus of the parietal cortex and the superior wall of the sylvian 
fissure. Perception and discrete localization of pain take place in these cortical areas. 
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2.3.6. Pain stimulus 
Pain can be stimulated by various means which include: 
• Mechanical 
• Thermal 
• Chemical 
2.3.6 (a) Cerebral Sensorv Cortex 
The function of cerebral sensory cortex is only to interpret pain. The pain can still persist 
even after complete removal of this cerebral sensory cortex. 
2.3.6 (b) Pain Suppression (Analgesia) 
Pain suppress1on is mediated through opioid receptors. The opioid receptors involved 
include mu, kappa, delta and gamma. Natural pain suppression in the body are provided by 
enkephal in, dynorphin and endorphin. 
2.3.6 (c) Spinal Cord and Higher Centre 
Areas that involved in the regulation of pain are hypothalamus, pituitary, brain stem and 
multiple areas in the brain. 
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2.3.7. Pain Sensation 
Pain measurement is very subjective and varies greatly from patient to patient. Various 
methods have been suggested to grade it because pain is complex perceptual experience 
rhat can only be quantified indirectly (Stoelting, R.K., 1999). 
Since pain has been operationalized in different ways in animal , human laboratory and 
clinical arenas of investigation has been vary limited. Measurement of pain in diseases 
should not be confused with measurement of experimental pain (Huskisson, E. C.. 1974). 
The physical pathology ts only one contribution to the expenence of pam. Pain is 
influenced by multiple facto rs such as cu ltural conditioning, expectations. social 
contingencies, mood state and perceptions of control (Turk, D.C.. 1993). 
It is easier to study experimental pain because it can be measured in terms of the intensity 
of the sri mulus. In case of pathological pain the nature of the stimulus is often unknown. its 
intensity is usually difficult to measure, and severi ty of the disease is not clearly related to 
pain because pain is modified by such facto rs as the individual patient' s pain th reshold 
(Huskisson. E.C., 1974). 
In all types of pain. accurate assessment is required to appropriately treat the patient. 
Unfortunately, the problem is not th is simple because there is no direct relationship 
between physical pathology and the integrity of pain . Pain is a subjective experience and 
there is no way to objectively quantify it (Turk, D.C., 1993). 
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2.3.8 Pain scoring system 
Various methods have been suggested to grade pain. They include: 
• Verbal Numerical Pain Score 
• Visual Analogue Score (VAS) 
• Functional Score 
• Observational Pain Score 
2.3.8 (a) Verbal Numerical Pain Score 
Patient is asked to give a score of 0 to I 0 by which: 
0 = no pain at al l 
I 0 = worst pain imaginable 
In th is study we used modified Verbal Numerical Score by using the num ber 0 to 4. The 
pain score is given as below: 
0 = 1 o Pain 
I = Sli (Jht Pain ;:, 
2 = Tolerable Pain 
3 = Bad Pain 
4 = Worst Pain 
This \1od ified Pain Score is a simple way, easy for patient to understand and response but 
may be less sensitive. 
' 
2.3.8 (b) Visual Analogue Score fVAS) 
some of the problems with the simple descriptive pain scale can be overcome by using 
either a visual analogue scale stretching from "no pain" to "pain as bad as it could be" 
(Huskisson, E.C., 1974). With the graphic rating method the intervals between the 
descriptive terms must usually be assessed, though it is possible to alter them to correct the 
abnormal distribution of results that may arise (Chapman, C.R. et al., 1985). This rating 
scale can be used quickly with minimal instructions to subjects and scored easily. 
Because of broad range of psychological experience is compressed into an artificially small 
continuum, subjects tend to spread responses over the entire scale regardless of the 
magnitude of the actual sensation (Chapman. C.R. eta/., 1985). 
Patient is asked to indicate the intensity of pain by marking a I Ocm line that labeled ·· no 
pain .. ar one end and "pain as bad as it could be'' at the other end (Huskisson, E.C. , 1974). 
Pain as bad as it could be 
No Pain 
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